Generic submissions under review
How to access a list of generic drug submissions currently under review.
Consult the Drug and vaccine authorizations for COVID-19: List of applications received to access submissions under review that are related to the COVID-19 pandemic.
On this page
- About the Generic Submissions Under Review (GSUR) list
- Finding information on the list
- Decisions
- Access to generic drugs
- Other lists of submissions under review
- Contact us
- View the list
About the Generic Submissions Under Review (GSUR) list
The Generic Submissions Under Review (GSUR) List helps to make our review processes more transparent. The list will help Canadians understand if generic versions of brand name drugs are currently under review in Canada.
The GSUR List was announced as part of Phase III of the Submissions Under Review (SUR) List initiative. A Notice was published in 2024 announcing the expansion of the GSUR List.
The GSUR List includes abbreviated new drug submissions (ANDSs) accepted into review on or after October 1, 2018.
Finding information on the list
The GSUR List entries each include the:
- medicinal ingredient(s)
- therapeutic area populated with the World Health Organization Anatomical Therapeutic Chemical code
- year and month the submission was accepted into review
- company (sponsor) name for ANDSs accepted into review on or after April 1, 2024 only (for all other submissions, the information is listed as 'not available')
The list is updated monthly.
Decisions
Submissions are added to the GSUR List after they have been accepted into review. They remain on the GSUR list through interim negative decisions and various administrative and/or regulatory holds. For more information about the submission process and review targets, refer to the Management of Drug Submissions and Applications Guidance.
A submission is removed from the GSUR List when:
- the submission is cancelled or
- a final decision is made and the submission is no longer under review
You can see if a submission has been approved in the Notice of Compliance Database.
Health Canada announced in August 2018 that it will publish regulatory decision summaries for final positive and negative decisions for certain prescription generic drug submissions that might be of interest to stakeholders. These can be found using the Regulatory Decision Summary search tool in the Drug and Health Product Register.
Access to generic drugs
Many factors affect Canadians' access to generic drugs. For more information about generic drug products and submissions, please see the Fact Sheet on Access to Generic Drugs in Canada.
External consultations
Several external consultations have been held throughout the evolution of the SUR List initiative. In 2017, an external consultation was held on five transparency proposals for prescription drugs. This report provides a summary of the consultation results. An additional consultation was held in 2019 to assess the use of adding the company (sponsor) name to the GSUR List and the resulting impacts on stakeholders.
Other lists of submissions under review
The Submissions Under Review (SUR) Lists include new drug submissions and supplemental new drug submissions for new uses. Click here for details and to access the Drug and health products submissions under review lists.
Contact us
Questions can be sent to us by email: opprs.enquiries-enquetes.bprse@hc-sc.gc.ca.
View the list
You can view the generic submissions under review list any time.
This list is current as of: 2024-11-30.
| Medicinal Ingredient(s) | Therapeutic Area | Year, Month Submission was Accepted into Review | Company Name (available for submissions accepted into review on or after April 1, 2024) |
|---|---|---|---|
| Abacavir sulfate, dolutegravir sodium, lamivudine | Antivirals for systemic use | 2021-04 | Not available |
| Abacavir sulfate, dolutegravir sodium, lamivudine | Antivirals for systemic use | 2023-03 | Not available |
| Abacavir sulfate, dolutegravir sodium, lamivudine | Antivirals for systemic use | 2024-08 | Apotex Inc |
| Abiraterone acetate | Endocrine therapy | 2023-10 | Not available |
| Acetaminophen | Analgesics | 2024-03 | Not available |
| Acyclovir | Antivirals for systemic use | 2022-01 | Not available |
| Acyclovir | Antivirals for systemic use | 2023-05 | Not available |
| Afatinib dimaleate | Antineoplastic agents | 2020-01 | Not available |
| Alectinib hydrochloride | Antineoplastic agents | 2022-11 | Not available |
| Alfacalcidol | Vitamins | 2023-08 | Not available |
| Almotriptan malate | Analgesics | 2022-08 | Not available |
| Amantadine hydrochloride | Anti-parkinson drugs | 2024-02 | Not available |
| Ambrisentan | Antihypertensives | 2022-12 | Not available |
| Amiodarone hydrochloride | Cardiac therapy | 2024-07 | JAMP Pharma Corporation |
| Amiodarone hydrochloride | Cardiac therapy | 2024-09 | Formative Pharma Inc. |
| Amlodipine besylate | Calcium channel blockers | 2024-08 | Teva Canada Limited |
| Amlodipine besylate, telmisartan | Agents acting on the renin-angiotensin system | 2022-12 | Not available |
| Amphotericin B | Antimycotics for systemic use | 2022-02 | Not available |
| Amphotericin B | Antimycotics for systemic use | 2024-07 | Marcan Pharmaceuticals Inc |
| Anastrozole | Endocrine therapy | 2022-11 | Not available |
| Apixaban | Antithrombotic agents | 2023-06 | Not available |
| Apremilast | Immunosuppressants | 2024-03 | Not available |
| Apremilast | Immunosuppressants | 2024-09 | Mint Pharmaceuticals Inc |
| Aprepitant | Antiemetics and antinauseants | 2023-01 | Not available |
| Argatroban | Antithrombotic agents | 2024-07 | Omega Laboratories Limited |
| Aripiprazole | Psycholeptics | 2023-12 | Not available |
| Aripiprazole | Psycholeptics | 2024-08 | Taro Pharmaceuticals Inc |
| Aripiprazole | Psycholeptics | 2024-09 | Apotex Inc |
| Arsenic trioxide | Antineoplastic agents | 2024-07 | Marcan Pharmaceuticals Inc |
| Atomoxetine hydrochloride | Psychoanaleptics | 2024-02 | Not available |
| Atovaquone | Antiprotozoals | 2023-04 | Not available |
| Atovaquone | Antiprotozoals | 2023-09 | Not available |
| Axitinib | Antineoplastic agents | 2024-02 | Not available |
| Azacitidine | Antineoplastic agents | 2024-04 | MSN Labs Canada Inc. |
| Azilsartan medoxomil | Agents acting on the renin-angiotensin system | 2022-03 | Not available |
| Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate | Antivirals for systemic use | 2024-08 | JAMP Pharma Corporation |
| Bilastine | Antihistamines for systemic use | 2023-10 | Not available |
| Bilastine | Antihistamines for systemic use | 2023-12 | Not available |
| Bilastine | Antihistamines for systemic use | 2024-02 | Not available |
| Bilastine | Antihistamines for systemic use | 2024-07 | JAMP Pharma Corporation |
| Bilastine | Antihistamines for systemic use | 2024-07 | Laboratoire Riva Inc |
| Bimatoprost | Ophthalmologicals | 2022-02 | Not available |
| Bimatoprost | Ophthalmologicals | 2023-06 | Not available |
| Bimatoprost | Ophthalmologicals | 2023-07 | Not available |
| Bimatoprost | Ophthalmologicals | 2024-11 | JAMP Pharma Corporation |
| Bortezomib | Antineoplastic agents | 2023-07 | Not available |
| Bosutinib | Antineoplastic agents | 2024-06 | Dr Reddys Laboratories Ltd |
| Bosutinib | Antineoplastic agents | 2024-10 | Taro Pharmaceuticals Inc |
| Brexpiprazole | Psycholeptics | 2023-04 | Not available |
| Brexpiprazole | Psycholeptics | 2023-04 | Not available |
| Brexpiprazole | Psycholeptics | 2023-04 | Not available |
| Brexpiprazole | Psycholeptics | 2023-04 | Not available |
| Brexpiprazole | Psycholeptics | 2023-05 | Not available |
| Brexpiprazole | Psycholeptics | 2023-05 | Not available |
| Brimonidine tartrate | Ophthalmologicals | 2023-04 | Not available |
| Brimonidine tartrate | Ophthalmologicals | 2024-11 | Angita Pharma Inc |
| Brimonidine tartrate, timolol maleate | Ophthalmologicals | 2023-07 | Not available |
| Brivaracetam | Antiepileptics | 2023-11 | Not available |
| Brivaracetam | Antiepileptics | 2024-09 | Pharmascience Inc |
| Buffer solution, melphalan hydrochloride | Antineoplastic agents | 2022-02 | Not available |
| Bupivacaine hydrochloride | Anesthetics | 2024-02 | Not available |
| Buprenorphine | Analgesics | 2024-01 | Not available |
| Bupropion hydrochloride | Psychoanaleptics | 2021-07 | Not available |
| Bupropion hydrochloride | Psychoanaleptics | 2023-04 | Not available |
| Bupropion hydrochloride | Psychoanaleptics | 2024-07 | Pharmascience Inc |
| Cabazitaxel | Antineoplastic agents | 2022-08 | Not available |
| Cabazitaxel | Antineoplastic agents | 2024-01 | Not available |
| Cabergoline | Other gynecologicals | 2024-08 | Nora Pharma Inc |
| Cabergoline | Other gynecologicals | 2024-10 | Mantra Pharma Inc. |
| Calcitrol | Vitamins | 2023-05 | Not available |
| Canagliflozin | Drugs used in diabetes | 2020-07 | Not available |
| Canagliflozin | Drugs used in diabetes | 2020-07 | Not available |
| Canagliflozin | Drugs used in diabetes | 2023-03 | Not available |
| Canagliflozin | Drugs used in diabetes | 2023-12 | Not available |
| Canagliflozin | Drugs used in diabetes | 2024-04 | Apotex Inc |
| Carbamazepine | Antiepileptics | 2024-10 | Auro Pharma Inc |
| Carbidopa, levodopa | Anti-Parkinson drugs | 2023-09 | Not available |
| Carfilzomib | Antineoplastic agents | 2022-03 | Not available |
| Carfilzomib | Antineoplastic agents | 2022-05 | Not available |
| Carfilzomib | Antineoplastic agents | 2022-06 | Not available |
| Carfilzomib | Antineoplastic agents | 2022-09 | Not available |
| Carfilzomib | Antineoplastic agents | 2023-06 | Not available |
| Carfilzomib | Antineoplastic agents | 2024-07 | Glenmark Pharmaceuticals Canada Inc. |
| Cefixime | Antibacterials for systemic use | 2023-09 | Not available |
| Cefixime | Antibacterials for systemic use | 2023-10 | Not available |
| Cefixime | Antibacterials for systemic use | 2024-01 | Not available |
| Celecoxib | Antiinflammatory and antirheumatic products | 2019-04 | Not available |
| Ciclopirox | Antifungals for dermatological use | 2023-04 | Not available |
| Cisatracurium besylate | Muscle relaxants | 2024-02 | Not available |
| Cladribine | Immunosuppressants | 2023-05 | Not available |
| Cladribine | Immunosuppressants | 2024-01 | Not available |
| Clindamycin phosphate | Antibacterials for systemic use | 2024-09 | Hikma Canada Limited |
| Clonidine hydrochloride | Antihypertensives | 2024-05 | JAMP Pharma Corporation |
| Clonidine hydrochloride | Antihypertensives | 2024-08 | Mint Pharmaceuticals Inc |
| Clopidogrel bisulfate | Antithrombotic agents | 2023-03 | Not available |
| Clozapine | Psycholeptics | 2021-11 | Not available |
| Cobicistat, elvitegravir, emtricitabine, tenofovir alafenamide | Antivirals for systemic use | 2023-09 | Not available |
| Colesevelam hydrochloride | Lipid modifying agents | 2021-05 | Not available |
| Colesevelam hydrochloride | Lipid modifying agents | 2024-06 | JAMP Pharma Corporation |
| Cyclophosphamide | Antineoplastic agents | 2022-12 | Not available |
| Cyclophosphamide | Antineoplastic agents | 2023-10 | Not available |
| Cyclophosphamide | Antineoplastic agents | 2024-01 | Not available |
| Cyclophosphamide monohydrate | Antineoplastic agents | 2024-04 | Formative Pharma Inc. |
| Cyproterone acetate, ethinyl estradiol | Sex hormones and modulators of the genital system | 2024-05 | Ambicare Pharmaceuticals Inc. |
| Dabigatran etexilate mesilate | Antithrombotic agents | 2024-05 | Auro Pharma Inc |
| Dacarbazine | Antineoplastic agents | 2024-08 | Sterimax Inc |
| Dapagliflozin | Drugs used in diabetes | 2023-10 | Not available |
| Dapagliflozin propanediol monohydrate | Drugs used in diabetes | 2024-11 | Nora Pharma Inc |
| Dasatinib | Antineoplastic agents | 2022-05 | Not available |
| Dasatinib | Antineoplastic agents | 2023-10 | Not available |
| Dasatinib monohydrate | Antineoplastic agents | 2024-05 | Eugia Pharma Inc. |
| Deferasirox | All other therapeutic products | 2021-11 | Not available |
| Degarelix acetate | Endocrine therapy | 2024-01 | Not available |
| Desmopressin acetate | Pituitary and hypothalamic hormones and analogues | 2022-05 | Not available |
| Desmopressin acetate | Pituitary and hypothalamic hormones and analogues | 2023-02 | Not available |
| Desmopressin acetate | Pituitary and hypothalamic hormones and analogues | 2023-10 | Not available |
| Desogestrel, ethinyl estradiol | Sex hormones and modulators of the genital system | 2024-08 | Ambicare Pharmaceuticals Inc. |
| Desvenlafaxine succinate | Psychoanaleptics | 2024-04 | Mint Pharmaceuticals Inc |
| Dexlansoprazole | Drugs for acid related disorders | 2024-05 | Sandoz Canada Incorporated |
| Dexmedetomidine | Psycholeptics | 2024-02 | Not available |
| Dexmedetomidine hydrochloride | Psycholeptics | 2022-09 | Not available |
| Dexmedetomidine hydrochloride | Psycholeptics | 2024-01 | Not available |
| Dexrazoxane | All other therapeutic products | 2024-08 | Hikma Canada Limited |
| Diclofenac potassium | Antiinflammatory and antirheumatic products | 2024-02 | Not available |
| Diclofenac potassium | Antiinflammatory and antirheumatic products | 2024-07 | JAMP Pharma Corporation |
| Digoxin | Cardiac therapy | 2024-07 | Auro Pharma Inc |
| Diltiazem hydrochloride | Calcium channel blockers | 2024-02 | Not available |
| Dobutamine hydrochloride | Cardiac therapy | 2024-03 | Not available |
| Dolutegravir | Antivirals for systemic use | 2020-01 | Not available |
| Dolutegravir sodium | Antivirals for systemic use | 2023-09 | Not available |
| Donepezil hydrochloride monohydrate | Psychoanaleptics | 2023-08 | Not available |
| Doxepin hydrochloride | Psychoanaleptics | 2023-08 | Not available |
| Doxepin hydrochloride | Psychoanaleptics | 2023-12 | Not available |
| Doxorubicin hydrochloride | Antineoplastic agents | 2024-05 | Accord Healthcare Inc |
| Doxycycline hyclate | Antibacterials for systemic use | 2023-05 | Not available |
| Doxycycline monohydrate | Antibacterials for systemic use | 2022-12 | Not available |
| Doxylamine succinate, pyridoxine hydrochloride | Antihistamines for systemic use | 2023-09 | Not available |
| Edoxaban tosylate | Antithrombotic agents | 2023-08 | Not available |
| Edoxaban tosylate | Antithrombotic agents | 2024-02 | Not available |
| Edoxaban tosylate | Antithrombotic agents | 2024-08 | Pharmascience Inc |
| Edoxaban tosylate | Antithrombotic agents | 2024-11 | Dr Reddys Laboratories Ltd |
| Edoxaban tosylate | Antithrombotic agents | 2024-11 | JAMP Pharma Corporation |
| Efinaconazole | Antifungals for dermatological use | 2019-11 | Not available |
| Efinaconazole | Antifungals for dermatological use | 2020-01 | Not available |
| Efinaconazole | Antifungals for dermatological use | 2020-02 | Not available |
| Efinaconazole | Antifungals for dermatological use | 2020-11 | Not available |
| Efinaconazole | Antifungals for dermatological use | 2020-12 | Not available |
| Efinaconazole | Antifungals for dermatological use | 2021-04 | Not available |
| Efinaconazole | Antifungals for dermatological use | 2022-03 | Not available |
| Efinaconazole | Antifungals for dermatological use | 2022-06 | Not available |
| Efinaconazole | Antifungals for dermatological use | 2023-05 | Not available |
| Eltrombopag olamine | Antihemorrhagics | 2023-09 | Not available |
| Eltrombopag olamine | Antihemorrhagics | 2024-02 | Not available |
| Eltrombopag olamine | Antihemorrhagics | 2024-04 | Dr Reddys Laboratories Ltd |
| Empagliflozin | Drugs used in diabetes | 2021-09 | Not available |
| Empagliflozin | Drugs used in diabetes | 2021-10 | Not available |
| Empagliflozin | Drugs used in diabetes | 2021-11 | Not available |
| Empagliflozin | Drugs used in diabetes | 2022-09 | Not available |
| Empagliflozin | Drugs used in diabetes | 2022-09 | Not available |
| Empagliflozin | Drugs used in diabetes | 2023-04 | Not available |
| Empagliflozin | Drugs used in diabetes | 2023-05 | Not available |
| Empagliflozin | Drugs used in diabetes | 2023-12 | Not available |
| Empagliflozin | Drugs used in diabetes | 2024-02 | Not available |
| Empagliflozin | Drugs used in diabetes | 2024-10 | Laboratoire Riva Inc |
| Empagliflozin, metformin hydrochloride | Drugs used in diabetes | 2021-10 | Not available |
| Emtricitabine, rilpivirine hydrochloride, tenofovir alafenamide hemifumarate | Antivirals for systemic use | 2022-04 | Not available |
| Emtricitabine, tenofovir alafenamide | Antivirals for systemic use | 2022-01 | Not available |
| Emtricitabine, tenofovir alafenamide fumarate | Antivirals for systemic use | 2022-04 | Not available |
| Emtricitabine, tenofovir alafenamide hemifumarate | Antivirals for systemic use | 2022-04 | Not available |
| Emtricitabine, tenofovir alafenamide hemifumarate | Antivirals for systemic use | 2022-07 | Not available |
| Enzalutamide | Endocrine therapy | 2019-06 | Not available |
| Enzalutamide | Endocrine therapy | 2020-10 | Not available |
| Enzalutamide | Endocrine therapy | 2022-04 | Not available |
| Enzalutamide | Endocrine therapy | 2024-09 | Dr Reddys Laboratories Ltd |
| Eplerenone | Diuretics | 2023-07 | Not available |
| Eribulin mesylate | Antineoplastic agents | 2023-05 | Not available |
| Eribulin mesylate | Antineoplastic agents | 2023-07 | Not available |
| Eribulin mesylate | Antineoplastic agents | 2023-12 | Not available |
| Eribulin mesylate | Antineoplastic agents | 2024-07 | Formative Pharma Inc. |
| Eslicarbazepine acetate | Antiepileptics | 2021-10 | Not available |
| Eslicarbazepine acetate | Antiepileptics | 2022-11 | Not available |
| Esomeprazole magnesium trihydrate | Drugs for acid related disorders | 2023-06 | Not available |
| Esomeprazole magnesium trihydrate, naproxen | Antiinflammatory and antirheumatic products | 2023-12 | Not available |
| Estradiol | Sex hormones and modulators of the genital system | 2023-05 | Not available |
| Estradiol hemihydrate, norethindrone acetate | Sex hormones and modulators of the genital system | 2024-09 | Novast Laboratories Ltd. |
| Ethinyl estradiol, etonogestrel | Other gynecologicals | 2021-08 | Not available |
| Ethinyl estradiol, etonogestrel | Other gynecologicals | 2024-01 | Not available |
| Ethinyl estradiol, norethindrone acetate | Sex hormones and modulators of the genital system | 2024-05 | Apotex Inc |
| Ethinyl estradiol, norethindrone acetate | Sex hormones and modulators of the genital system | 2024-08 | Lupin Pharma Canada Limited |
| Ethinyl estradiol, norgestimate | Sex hormones and modulators of the genital system | 2024-06 | Lupin Pharma Canada Limited |
| Fampridine | Other nervous system drugs | 2024-06 | Auro Pharma Inc |
| Fenofibrate | Lipid modifying agents | 2022-05 | Not available |
| Fenofibrate | Lipid modifying agents | 2024-01 | Not available |
| Fenofibrate | Lipid modifying agents | 2024-09 | Nora Pharma Inc |
| Fesoterodine fumarate | Urologicals | 2024-01 | Not available |
| Finasteride | Other dermatological preparations | 2023-05 | Not available |
| Fingolimod hydrochloride | Immunosuppressants | 2019-06 | Not available |
| Fluconazole | Antimycotics for systemic use | 2023-05 | Not available |
| Fludrocortisone 21-acetate | Corticosteroids for systemic use | 2024-05 | Mint Pharmaceuticals Inc |
| Fludrocortisone 21-acetate | Corticosteroids for systemic use | 2024-08 | Marcan Pharmaceuticals Inc |
| Fluoxetine hydrochloride | Psychoanaleptics | 2023-02 | Not available |
| Fluticasone propionate | Nasal preparations | 2024-09 | Hikma Canada Limited |
| Formoterol fumarate dihydrate, mometasone furoate | Drugs for obstructive airway diseases | 2024-05 | Lupin Pharma Canada Limited |
| Fosfomycin | Antibacterials for systemic use | 2023-08 | Not available |
| Fulvestrant | Endocrine therapy | 2024-03 | Not available |
| Galantamine hydrobromide | Psychoanaleptics | 2023-08 | Not available |
| Ganirelix acetate | Pituitary and hypothalamic hormones and analogues | 2024-02 | Not available |
| Ganirelix acetate | Pituitary and hypothalamic hormones and analogues | 2024-05 | Sun Pharma Canada Inc |
| Gemcitabine hydrochloride | Antineoplastic agents | 2023-05 | Not available |
| Glatiramer acetate | Immunostimulants | 2020-11 | Not available |
| Glycopyrronium bromide | Drugs for obstructive airway diseases | 2024-01 | Not available |
| Granisetron hydrochloride | Antiemetics and antinauseants | 2023-02 | Not available |
| Guanfacine hydrochloride | Antihypertensives | 2023-09 | Not available |
| Guanfacine hydrochloride | Antihypertensives | 2023-09 | Not available |
| Haloperidol | Psycholeptics | 2024-07 | Nora Pharma Inc |
| Haloperidol decanoate | Psycholeptics | 2023-03 | Not available |
| Hydromorphone hydrochloride | Analgesics | 2022-09 | Not available |
| Hydromorphone hydrochloride | Analgesics | 2024-04 | Pharmascience Inc |
| Hydroxychloroquine sulfate | Antiprotozoals | 2023-06 | Not available |
| Hyoscine butylbromide | Drugs for functional gastrointestinal disorders | 2023-03 | Not available |
| Hyoscine butylbromide | Drugs for functional gastrointestinal disorders | 2023-05 | Not available |
| Ibrutinib | Antineoplastic agents | 2021-01 | Not available |
| Ibrutinib | Antineoplastic agents | 2021-05 | Not available |
| Ibrutinib | Antineoplastic agents | 2021-06 | Not available |
| Ibrutinib | Antineoplastic agents | 2022-11 | Not available |
| Indapamide | Diuretics | 2023-05 | Not available |
| Indapamide, perindopril erbumine | Agents acting on the renin-angiotensin system | 2022-05 | Not available |
| Iodixanol | Contrast media | 2024-02 | Not available |
| Iron (III)-hydroxide sucrose complex | Antianemic preparations | 2024-01 | Not available |
| Isosorbide-5-monohydrate | Cardiac therapy | 2024-01 | Not available |
| Ivacaftor | Other respiratory system products | 2024-11 | Sandoz Canada Incorporated |
| Ivermectin | Other dermatological preparations | 2024-08 | Zydus Lifesciences Limited |
| Ketorolac tromethamine | Antiinflammatory and antirheumatic products | 2024-05 | Ambicare Pharmaceuticals Inc. |
| Lacosamide | Antiepileptics | 2024-06 | Eugia Pharma Inc. |
| Lacosamide | Antiepileptics | 2024-10 | Formative Pharma Inc. |
| Lamotrigine | Antiepileptics | 2023-10 | Not available |
| Lanreotide acetate | Pituitary and hypothalamic hormones and analogues | 2023-07 | Not available |
| Lansoprazole | Drugs for acid related disorders | 2023-11 | Not available |
| Latanoprost, timolol maleate | Ophthalmologicals | 2021-12 | Not available |
| Leflunomide | Immunosuppressants | 2023-08 | Not available |
| Lenvatinib mesylate | Antineoplastic agents | 2024-05 | Dr Reddys Laboratories Ltd |
| Letermovir | Antivirals for systemic use | 2024-02 | Not available |
| Leucovorin calcium | All other therapeutic products | 2023-04 | Not available |
| Leucovorin calcium | All other therapeutic products | 2023-11 | Not available |
| Leucovorin calcium | All other therapeutic products | 2024-07 | JAMP Pharma Corporation |
| Levetiracetam | Antiepileptics | 2021-10 | Not available |
| Levetiracetam | Antiepileptics | 2023-01 | Not available |
| Levetiracetam | Antiepileptics | 2023-01 | Not available |
| Levetiracetam | Antiepileptics | 2023-10 | Not available |
| Levetiracetam | Antiepileptics | 2024-01 | Not available |
| Levetiracetam | Antiepileptics | 2024-04 | Marcan Pharmaceuticals Inc |
| Levetiracetam | Antiepileptics | 2024-05 | JAMP Pharma Corporation |
| Levocabastine | Other alimentary tract and metabolism products | 2023-12 | Not available |
| Levofloxacin hemihydrate | Antibacterials for systemic use | 2024-09 | InfoRLife SA |
| Levomilnacipran | Psychoanaleptics | 2024-10 | Apotex Inc |
| Levothyroxine sodium | Thyroid therapy | 2023-11 | Not available |
| Levothyroxine sodium | Thyroid therapy | 2024-04 | Genix Pharmaceuticals Corporation |
| Lidocaine, prilocaine | Antipruritics, including antihistamines, anesthetics, etc. | 2022-02 | Not available |
| Lifitegrast | Ophthalmologicals | 2024-05 | Micro Labs Limited |
| Linagliptin | Drugs used in diabetes | 2020-01 | Not available |
| Linagliptin | Drugs used in diabetes | 2020-10 | Not available |
| Linagliptin | Drugs used in diabetes | 2021-09 | Not available |
| Linagliptin | Drugs used in diabetes | 2022-05 | Not available |
| Linagliptin | Drugs used in diabetes | 2022-05 | Not available |
| Linagliptin | Drugs used in diabetes | 2023-01 | Not available |
| Linagliptin | Drugs used in diabetes | 2023-06 | Not available |
| Linagliptin | Drugs used in diabetes | 2023-08 | Not available |
| Linagliptin | Drugs used in diabetes | 2023-10 | Not available |
| Linagliptin | Drugs used in diabetes | 2024-05 | Nora Pharma Inc |
| Linagliptin | Drugs used in diabetes | 2024-06 | Dr Reddys Laboratories Ltd |
| Linagliptin, metformin hydrochloride | Drugs used in diabetes | 2021-10 | Not available |
| Linagliptin, metformin hydrochloride | Drugs used in diabetes | 2023-09 | Not available |
| Linagliptin, metformin hydrochloride | Drugs used in diabetes | 2024-01 | Not available |
| Liothyronine sodium | Thyroid therapy | 2023-05 | Not available |
| Liothyronine sodium | Thyroid therapy | 2024-06 | Taro Pharmaceuticals Inc |
| Liothyronine sodium | Thyroid therapy | 2024-11 | Accord Healthcare Inc |
| Liraglutide | Drugs used in diabetes | 2023-11 | Not available |
| Liraglutide | Drugs used in diabetes | 2024-04 | Dr Reddys Laboratories Ltd |
| Liraglutide | Drugs used in diabetes | 2024-08 | Biocon Pharma Limited |
| Liraglutide | Drugs used in diabetes | 2024-08 | Biocon Pharma Limited |
| Liraglutide | Drugs used in diabetes | 2024-09 | Fresenius Kabi Canada Ltd |
| Lorazepam | Psycholeptics | 2024-08 | Juno Pharmaceuticals Corp. |
| Macitentan | Antihypertensives | 2020-01 | Not available |
| Macitentan | Antihypertensives | 2020-02 | Not available |
| Macitentan | Antihypertensives | 2020-06 | Not available |
| Macitentan | Antihypertensives | 2021-11 | Not available |
| Macitentan | Antihypertensives | 2021-12 | Not available |
| Macitentan | Antihypertensives | 2022-01 | Not available |
| Macitentan | Antihypertensives | 2024-09 | Pharmascience Inc |
| Maraviroc | Antivirals for systemic use | 2024-07 | Waymade Canada Inc. |
| Medroxyprogesterone acetate | Sex hormones and modulators of the genital system | 2024-07 | Accord Healthcare Inc |
| Melphalan hydrochloride | Antineoplastic agents | 2024-03 | Not available |
| Mesalazine | Antidiarrheals, intestinal anti-inflammatory/anti-infective agents | 2022-05 | Not available |
| Metformin hydrochloride | Drugs used in diabetes | 2024-05 | Glenmark Pharmaceuticals Canada Inc. |
| Metformin hydrochloride | Drugs used in diabetes | 2024-11 | Lupin Pharma Canada Limited |
| Metformin hydrochloride, sitagliptin | Drugs used in diabetes | 2022-05 | Not available |
| Metformin hydrochloride, sitagliptin | Drugs used in diabetes | 2024-09 | JAMP Pharma Corporation |
| Metformin hydrochloride, sitagliptin phosphate monohydrate | Drugs used in diabetes | 2022-12 | Not available |
| Methadone hydrochloride | Other nervous system drugs | 2021-07 | Not available |
| Methadone hydrochloride | Other nervous system drugs | 2024-05 | Pharmascience Inc |
| Methotrexate | Antineoplastic agents | 2022-12 | Not available |
| Methotrexate | Antineoplastic agents | 2023-04 | Not available |
| Methotrexate | Antineoplastic agents | 2023-07 | Not available |
| Methotrexate disodium | Antineoplastic agents | 2023-07 | Not available |
| Methotrexate disodium | Antineoplastic agents | 2024-02 | Not available |
| Methylphenidate hydrochloride | Psychoanaleptics | 2022-03 | Not available |
| Methylprednisolone sodium succinate | Corticosteroids for systemic use | 2023-10 | Not available |
| Metronidazole | Antibacterials for systemic use | 2024-01 | Not available |
| Metronidazole | Antibiotics and chemotherapy for dermatological use | 2024-08 | Taro Pharmaceuticals Inc |
| Micafungin sodium | Antimycotics for systemic use | 2023-02 | Not available |
| Midazolam | Psycholeptics | 2024-08 | Sterimax Inc |
| Mifepristone, misoprostol | Sex hormones and modulators of the genital system | 2024-07 | Lupin Pharma Canada Limited |
| Mifepristone, misoprostol | Sex hormones and modulators of the genital system | 2024-09 | JAMP Pharma Corporation |
| Miglustat | Other alimentary tract and metabolism products | 2024-08 | Waymade Canada Inc. |
| Mirabegron | Urologicals | 2022-09 | Not available |
| Mirabegron | Urologicals | 2023-07 | Not available |
| Mirtazapine | Psychoanaleptics | 2023-10 | Not available |
| Mitomycin | Antineoplastic agents | 2024-10 | Eugia Pharma Inc. |
| Moxifloxacin hydrochloride | Ophthalmologicals | 2023-07 | Not available |
| Moxifloxacin hydrochloride | Antibacterials for systemic use | 2023-11 | Not available |
| Mycophenolate mofetil | Immunosuppressants | 2023-02 | Not available |
| Mycophenolate mofetil | Immunosuppressants | 2024-06 | JAMP Pharma Corporation |
| Mycophenolic acid | Immunosuppressants | 2024-05 | Auro Pharma Inc |
| Nadolol | Beta blocking agents | 2021-11 | Not available |
| Naloxegol | Drugs for constipation | 2021-08 | Not available |
| Naloxone hydrochloride | All other therapeutic products | 2023-11 | Not available |
| Naloxone hydrochloride dihydrate | All other therapeutic products | 2022-10 | Not available |
| Naloxone hydrochloride dihydrate | All other therapeutic products | 2024-01 | Not available |
| Naltrexone hydrochloride | Other nervous system drugs | 2023-11 | Not available |
| Naratriptan hydrochloride | Analgesics | 2023-07 | Not available |
| Nelarabine | Antineoplastic agents | 2022-08 | Not available |
| Nifedipine | Calcium channel blockers | 2023-05 | Not available |
| Nifedipine | Calcium channel blockers | 2023-06 | Not available |
| Nifedipine | Calcium channel blockers | 2024-11 | Pharmascience Inc |
| Nilotinib hydrochloride dihydrate | Antineoplastic agents | 2024-07 | Pharmascience Inc |
| Nilotinib hydrochloride monohydrate | Antineoplastic agents | 2023-01 | Not available |
| Nilotinib hydrochloride monohydrate | Antineoplastic agents | 2023-07 | Not available |
| Nintedanib | Antineoplastic agents | 2021-10 | Not available |
| Nintedanib esylate | Antineoplastic agents | 2023-06 | Not available |
| Nintedanib esylate | Antineoplastic agents | 2024-05 | Dr Reddys Laboratories Ltd |
| Nortriptyline hydrochloride | Psychoanaleptics | 2022-11 | Not available |
| Nortriptyline hydrochloride | Psychoanaleptics | 2023-05 | Not available |
| Obeticholic acid | Bile and liver therapy | 2024-09 | Apotex Inc |
| Octreotide acetate | Pituitary and hypothalamic hormones and analogues | 2024-04 | Sterimax Inc |
| Ofloxacin | Ophthalmologicals | 2024-11 | Mantra Pharma Inc. |
| Olanzapine | Psychleptics | 2024-08 | Teva Canada Limited |
| Olaparib | Antineoplastic agents | 2024-08 | Sandoz Canada Incorporated |
| Olopatadine hydrochloride | Ophthalmologicals | 2022-03 | Not available |
| Olopatadine hydrochloride | Ophthalmologicals | 2023-05 | Not available |
| Olopatadine hydrochloride | Ophthalmologicals | 2023-08 | Not available |
| Ondansetron | Antiemetics and antinauseants | 2024-06 | JAMP Pharma Corporation |
| Ondansetron hydrochloride | Antiemetics and antinauseants | 2024-02 | Not available |
| Ondansetron hydrochloride dihydrate | Antiemetics and antinauseants | 2024-07 | JAMP Pharma Corporation |
| Oxcarbazepine | Antiepileptics | 2024-05 | JAMP Pharma Corporation |
| Oxybutynin chloride | Urologicals | 2023-05 | Not available |
| Paclitaxel | Antineoplastic agents | 2024-09 | Accord Healthcare Inc |
| Palbociclib | Antineoplastic agents | 2023-01 | Not available |
| Palbociclib | Antineoplastic agents | 2023-11 | Not available |
| Palbociclib | Antineoplastic agents | 2023-11 | Not available |
| Paliperidone | Psycholeptics | 2020-09 | Not available |
| Paliperidone | Psycholeptics | 2024-01 | Not available |
| Paliperidone palmitate | Psycholeptics | 2020-09 | Not available |
| Paliperidone palmitate | Psycholeptics | 2020-11 | Not available |
| Paliperidone palmitate | Psycholeptics | 2021-06 | Not available |
| Pamidronate disodium | Drugs for treatment of bone diseases | 2023-10 | Not available |
| Pantoprazole magnesium | Drugs for acid related disorders | 2024-01 | Not available |
| Pazopanib hydrochloride | Antineoplastic agents | 2024-05 | Dr Reddys Laboratories Ltd |
| Pemetrexed disodium | Antineoplastic agents | 2024-02 | Not available |
| Pemetrexed disodium hemipentahydrate, pemetrexed disodium heptahydrate | Antineoplastic agents | 2024-07 | Formative Pharma Inc. |
| Piperacillin sodium, tazobactam sodium | Antibacterials for systemic use | 2024-08 | Fresenius Kabi Canada Ltd |
| Pomalidomide | Immunosuppressants | 2021-03 | Not available |
| Ponatinib hydrochloride | Antineoplastic agents | 2024-06 | Apotex Inc |
| Posaconazole | Antimycotics for systemic use | 2022-12 | Not available |
| Pravastatin sodium | Lipid modifying agents | 2023-05 | Not available |
| Propofol | Anesthetics | 2024-10 | Sterimax Inc |
| Ranolazine | Cardiac therapy | 2024-06 | Marcan Pharmaceuticals Inc |
| Regorafenib | Antineoplastic agents | 2022-04 | Not available |
| Regorafenib | Antineoplastic agents | 2024-11 | Dr Reddys Laboratories Ltd |
| Ribociclib succinate | Antineoplastic agents | 2024-04 | Natco Pharma (Canada) Inc |
| Rivaroxaban | Antithrombotic agents | 2022-11 | Not available |
| Rivaroxaban | Antithrombotic agents | 2023-01 | Not available |
| Rivaroxaban | Antithrombotic agents | 2023-05 | Not available |
| Rufinamide | Antiepileptics | 2024-10 | Hikma Canada Limited |
| Rupatadine fumarate | Antihistamines for systemic use | 2022-09 | Not available |
| Rupatadine fumarate | Antihistamines for systemic use | 2024-04 | Pharmascience Inc |
| Rupatadine fumarate | Antihistamines for systemic use | 2024-05 | Apotex Inc |
| Ruxolitinib mesylate | Antineoplastic agents | 2024-06 | Apotex Inc |
| Ruxolitinib phosphate | Antineoplastic agents | 2023-04 | Not available |
| Sacubitril, valsartan | Agents acting on the renin-angiotensin system | 2023-01 | Not available |
| Sacubitril, valsartan | Agents acting on the renin-angiotensin system | 2024-05 | Mylan Pharmaceuticals ULC |
| Sapropterin dihydrochloride | Other alimentary tract and metabolism products | 2023-10 | Not available |
| Sapropterin dihydrochloride | Other alimentary tract and metabolism products | 2024-11 | JAMP Pharma Corporation |
| Saxagliptin | Drugs used in diabetes | 2024-01 | Not available |
| Saxagliptin hydrochloride | Drugs used in diabetes | 2023-09 | Not available |
| Selenious acid | Mineral supplements | 2024-11 | Fresenius Kabi Canada Ltd |
| Selexipag | Antithrombotic agents | 2022-08 | Not available |
| Semaglutide | Drugs used in diabetes | 2024-02 | Not available |
| Semaglutide | Drugs used in diabetes | 2024-03 | Not available |
| Semaglutide | Drugs used in diabetes | 2024-11 | Sandoz Canada Incorporated |
| Sertraline hydrochloride | Psychoanaleptics | 2024-09 | JAMP Pharma Corporation |
| Sevelamer carbonate | All other therapeutic products | 2022-04 | Not available |
| Sevelamer hydrochloride | All other therapeutic products | 2023-08 | Not available |
| Sildenafil citrate | Antihypertensives | 2023-07 | Not available |
| Sildenafil citrate | Urologicals | 2024-08 | JAMP Pharma Corporation |
| Sitagliptin | Drugs used in diabetes | 2022-04 | Not available |
| Sitagliptin phosphate | Drugs used in diabetes | 2023-05 | Not available |
| Sitagliptin phosphate monohydrate | Drugs used in diabetes | 2023-09 | Not available |
| Spironolactone | Diuretics | 2024-03 | Not available |
| Sugammadex sodium | All other therapeutic products | 2022-03 | Not available |
| Sugammadex sodium | All other therapeutic products | 2023-07 | Not available |
| Sugammadex sodium | All other therapeutic products | 2023-09 | Not available |
| Sugammadex sodium | All other therapeutic products | 2023-10 | Not available |
| Sugammadex sodium | All other therapeutic products | 2023-12 | Not available |
| Sugammadex sodium | All other therapeutic products | 2024-07 | Sterimax Inc |
| Sunitinib malate | Antineoplastic agents | 2023-11 | Not available |
| Tacrolimus | Immunosuppressants | 2023-10 | Not available |
| Tacrolimus | Other dermatological preparations | 2021-03 | Not available |
| Tadalafil | Urologicals | 2023-12 | Not available |
| Tadalafil | Urologicals | 2024-01 | Not available |
| Tamsulosin hydrochloride | Urologicals | 2024-02 | Not available |
| Tenofovir alafenamide fumarate | Antivirals for systemic use | 2022-01 | Not available |
| Tenofovir alafenamide fumarate | Antivirals for systemic use | 2022-01 | Not available |
| Tenofovir alafenamide fumarate | Antivirals for systemic use | 2022-07 | Not available |
| Tenofovir disoproxil fumarate | Antivirals for systemic use | 2024-06 | Generic Medical Partners Inc |
| Terazosin hydrochloride | Urologicals | 2024-10 | JAMP Pharma Corporation |
| Terbinafine hydrochloride | Antifungals for dermatological use | 2022-07 | Not available |
| Terbinafine hydrochloride | Antifungals for dermatological use | 2022-04 | Not available |
| Teriflunomide | Immunosuppressants | 2024-04 | Accel Pharma Inc |
| Teriflunomide | Immunosuppressants | 2024-08 | Mint Pharmaceuticals Inc |
| Teriparatide acetate | Calcium homeostasis | 2023-09 | Not available |
| Testosterone enanthate | Sex hormones and modulators of the genital system | 2023-05 | Not available |
| Ticagrelor | Antithrombotic agents | 2023-09 | Not available |
| Ticagrelor | Antithrombotic agents | 2024-02 | Not available |
| Timolol maleate, travoprost | Ophthalmologicals | 2023-05 | Not available |
| Tipiracil hydrochloride, trifluridine | Antineoplastic agents | 2024-03 | Not available |
| Tipiracil hydrochloride, trifluridine | Antineoplastic agents | 2024-05 | Pharmascience Inc |
| Tobramycin | Antibacterials for systemic use | 2023-10 | Not available |
| Tofacitinib citrate | Immunosuppressants | 2023-10 | Not available |
| Tofacitinib citrate | Immunosuppressants | 2024-02 | Not available |
| Tofacitinib citrate | Immunosuppressants | 2024-06 | MSN Labs Canada Inc. |
| Tolvaptan | Diuretics | 2023-11 | Not available |
| Trabectedin | Antineoplastic agents | 2021-04 | Not available |
| Tranexamic acid | Antihemorrhagics | 2023-04 | Not available |
| Tranexamic acid | Antihemorrhagics | 2024-10 | Fresenius Kabi Canada Ltd |
| Travoprost | Ophthalmologicals | 2023-04 | Not available |
| Treosulfan | Antineoplastic agents | 2023-06 | Not available |
| Treprostinil sodium | Antithrombotic agents | 2024-08 | Marcan Pharmaceuticals Inc |
| Valsartan | Agents acting on the renin-angiotensin system | 2024-07 | JAMP Pharma Corporation |
| Vancomycin hydrochloride | Antibacterials for systemic use | 2022-03 | Not available |
| Varenicline tartrate | Other nervous system drugs | 2024-07 | Auro Pharma Inc |
| Vortioxetine hydrobromide | Psychoanaleptics | 2024-05 | Apotex Inc |
| Vortioxetine hydrobromide | Psychanaleptics | 2024-08 | JAMP Pharma Corporation |
| Zopiclone | Psycholeptics | 2023-11 | Not available |
| Zopiclone | Psycholeptics | 2024-07 | Auro Pharma Inc |
Page details
- Date modified: